CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 45 enrolled
Drug / intervention
voriconazoledrug
Likely dose
Not stated in record
Key inclusion· 2
  • ✓History of proven or probable invasive fungal infection within the previous 12 months
  • ✓Undergoing allogeneic stem cell transplant for a hematological disease
Key exclusion· 6
  • ✕Pregnant or lactating women
  • ✕Severe disease other than the underlying hematological condition
  • ✕Active, symptomatic, uncontrolled invasive fungal infection
  • ✕Any evidence of active fungal disease per MSG-EORTC criteria

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00143312
NCT00143312Phase 4Completed
CompareCT.gov

Prospective, Open-Label, Non-Comparative, Multicenter Study for the Secondary Prophylaxis of Invasive Fungal Infections (IFI) With Voriconazole in Patients With Allogeneic Stem Cell Transplants (SCT).

Pfizer·interventional·Posted Sep 2, 2005·Updated Oct 6, 2009

In Brief

A Phase 4 clinical trial evaluating voriconazole for Prophylaxis Of Invasive Fungal Infections. Completed, enrolled 45 participants across 17 sites in 8 countries.

Detailed Summary

To prevent recurrence of invasive fungal infection in patients with allogeneic stem cell transplants

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProphylaxis Of Invasive Fungal Infections
CountriesBelgium, France, Germany, Portugal, Spain, Sweden, Switzerland, United Kingdom
CollaboratorsEuropean Society for Blood and Marrow Transplantation

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 2, 2005
Enrollment StartFeb 1, 2005
Primary CompletionApr 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 20.8 years ago

Interventions

voriconazoledrug

Voriconazole is given to patients at least 48 hours after chemotherapy